Aerie's M&A Potential Rises As Roclatan Passes Second Phase III Glaucoma Test
Executive Summary
Positive Phase III data for Aerie's second glaucoma drug candidate Roclatan – which will support a US FDA submission in the first half of 2018 – have boosted the California company's M&A allure.
You may also be interested in...
Aerie Looks To Grow Its Two Glaucoma Products In Tandem
The approval of combo therapy Rocklatan gives Aerie two approved glaucoma products; Rhopressa quickly attained wide market access in the US and Aerie expects Rocklatan to fare the same.
Keeping Track: Thumbs Up For Abbvie and GSK; Thumbs Down For Insys
The latest drug development news and highlights from our US FDA Performance Tracker.
Aerie's Netarsudil Headed For Broad Indication With Only Subpopulation Efficacy
US FDA's Dermatologic and Ophthalmologic Drugs Advisory Committee votes in favor of efficacy of proposed glaucoma treatment, but several say only in patients with baseline intraocular pressure less than 25 mmHg.